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Lung cancer affects over 1. 8 million people worldwide and is the leading cause
of cancer related mortality globally. Currently, diagnosis of lung cancer involves a
combination of imaging and invasive biopsies to confirm histopathology. Non-invasive
diagnostic techniques under investigation include “liquid biopsies” through a simple
blood draw to develop predictive and prognostic biomarkers. A better understanding
of circulating tumor cell (CTC) dissemination mechanisms offers promising potential for
the development of techniques to assist in the diagnosis of lung cancer. Enumeration
and characterization of CTCs has the potential to act as a prognostic biomarker and
to identify novel drug targets for a precision medicine approach to lung cancer care.
This review will focus on the current status of CTCs and their potential diagnostic and
prognostic utility in this setting.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality among men and women worldwide
(1). In 2012, the incidence was estimated at 1.8 million new cases, accounting for 12.9% of all new
cancers diagnosed globally (2). There is an estimated 18% survival rate beyond 5 years for all stages
combined, with poor outcomes largely due to late diagnosis (1, 3). The majority of patients present
with locally advanced or metastatic disease, with ∼20–30% of patients presenting with early stage
disease (3, 4). Late diagnosis is a major underlying cause for this advanced disease presentation
(5). The annual mortality rate for lung cancer is higher than for colon, breast, and prostate cancers
combined (6). The majority of patients presenting with advanced stage at diagnosis contributes to
this poor outcome (4).
There are two main types of lung cancers, small cell lung carcinoma (SCLC) and non-small cell
carcinoma (NSCLC). NSCLC is the most common, accounting for 80% of cases (7). NSCLC has
three main histological subtypes: adenocarcinoma, squamous cell (epidermoid) carcinoma, and
large cell undifferentiated carcinoma. Adenocarcinoma accounts for ∼40% of cases although is
increasing in relative incidence, and usually starts in mucus secreting epithelial cells (167). The
prognosis of NSCLC subtypes depends on the stage of the tumor and the treatment availability.
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Small cell lung cancer (SCLC) accounts for about 15% of
all lung cancers diagnosed annually and up to 25% of lung
cancer deaths. SCLC is characterized by amore aggressive clinical
phenotype than NSCLC with progression to metastatic disease
earlier in the disease course (8).
SCLC and NSCLC arise from different cell types and
demonstrate varying clinical features as shown in Table 1.
Lung cancer may be initiated through exposure to
carcinogens. The main risk factor for lung cancer is the
use of tobacco. Tobacco is known to initiate and promote
carcinogenesis and accounts for 85% of lung cancer cases (9).
Additional known risks include exposure to pollutants such
as asbestos, tar and metals including arsenic, and chromium.
Common symptoms include persistent cough, worsening
breathing, pneumonia that fails to resolve, chest discomfort,
wheezing, blood in the sputum, and hoarseness (3, 10). A
minority are asymptomatic, detected by chance through
investigation of other illnesses or in screening programs (11).
Treatment options depend on the intent of treatment
and may include loco-regional treatment such as surgery,
image guided ablation including radical chemo-radiotherapy,
stereotactic ablative radiation treatment, thermal ablation or
cryotherapy, or systemic treatment such as chemotherapy,
targeted agents, and immunotherapy, alongside novel agents
under current investigation in clinical trials (11). An example of
the power of targeted therapies in a precision medicine approach
was demonstrated in 2004 by Lynch et al. (12) and Paez et
al. (13) who demonstrated that patients with EGFR mutations
present in the tumors of patients with non-small cell lung
cancer exhibited a dramatic response to getfitinib, the epidermal
growth factor (EGFR) tyrosine kinase inhibitor (TKI), bringing
personalized medicine to reality for a subset of NSCLC patients
(12, 13).
TABLE 1 | Lung cancer classification.
Location in the lung Common features Common
mutations
NSCLC (80–85%) Adenocarcinoma (40%) Peripheral • Most common type of cancer
in non- smokers
• More common in women
• Should test for EGFR, ALK,















Peripheral • Similar characteristics to
adenocarcinoma
SCLC (15–20%) Central • Strongest association with
smoking
• Very rapid growth
• Early distant metastasis in
brain, liver and bone
• Worst prognosis







Utilization of expensive systemic targeted therapies, however,
has traditionally required invasive biopsies in order to assess
for targetable tumoral aberrations. This presents a challenge
for the monitoring of lung cancers due to the requirement for
longitudinal sampling of tumors (14).
METASTASIS AND
EPITHELIAL-MESENCHYMAL TRANSITION
Metastasis is an extremely complex, multistep process. Cells
must gain the ability to intravasate into the blood from the
bulk tumor, travel through the blood undergoing sheer stressors
and immune evasion, and extravasate to favorable metastatic
sites such as bone, brain and liver (15–17). In order to detach
from the primary tumor and disseminate into the blood,
cells must undergo a cellular process known as epithelial-
mesenchymal transition (EMT) (18). EMT enables tumor cells
to become motile and enhances migratory capabilities which
in effect allows cells to penetrate into the lymph vasculature
and circulate as single or clusters of circulating tumor cells
(CTCs) (19). Whilst in blood, CTCs exist in a dynamic EMT
state (20). CTCs extravasate having undergone the reverse
process known as mesenchymal to epithelial transition (MET)
and colonize at distant organs, (21). EMT is thought to
support cell invasiveness but restrict proliferation, thereby
maintaining cancer cell survival in metastatic sites whereas
MET re-activates proliferative potential (22). The famous “seed
and soil” hypothesis proposed by Stephen Pagent in the
Nineteenth century suggesting that tumor cells (the “seed”)
have a preference to metastasize in certain organs (the ‘soil)
(23). This hypothesis has since been revisited by Fidler and
Langly, still holding significance in cancer research today
(24, 25).
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CIRCULATING TUMOR CELLS IN LUNG
CANCER
CTCs were first described by an Australian physician, Thomas
Ashworth in 1869, where cancer cells in the blood were observed
which resembled the cells of the primary tumor (26). CTCs play
a central role in the metastatic spread of lung cancer, that is
ultimately responsible for patient morbidity and mortality from
the disease (27). While the concept of CTCs were described over
one hundred years ago, it is only recently that they have been
utilized in cancer diagnosis and prognosis (28).
Evidence has shown that the presence of CTCs in the blood
correlates with poor overall survival in patients with metastatic
prostate, breast and colon cancers (29–31). Patients with SCLC
have on average 10 timesmore CTCs than patients with any other
tumor type (32–34).
Molecular targeted therapies such as tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR) mutants and
anaplastic lymphoma kinase (ALK) inhibitors in ALK rearranged
NSCLC patients have recently advanced the management of lung
cancer for a limited proportion of patients (35–39). To determine
eligibility for such targeted therapies, tumor biopsies have
traditionally been necessary, increasing the likelihood of biopsy-
related complications (40). Even in patients developing resistance
to first line EGFR TKIs, liquid biopsies using circulating tumor
DNA plasma only detect T790M mutations in ∼80% of cases,
particularly in low volume disease, making a repeat biopsy
necessary. Tumor heterogeneity within the primary site or
between primary and metastatic sites, can also create potential
sampling bias, which may mask the true genetic profile of
the cancer. The prospect of longitudinal sampling in order
to monitor for the development of therapeutic resistance to
treatments is likewise limited if invasive biopsies are essential
(41, 42).
Use of CTCs as a liquid biopsy is promising for serial
assessment of tumor evolution during the course of the disease
and during systemic treatment in a less invasive, real-time
manner, by a simple blood draw (19, 43). This liquid biopsy also
provides potential for the early diagnosis of cancer and valuable
insights into tumor heterogeneity and genomic diversity for the
early diagnosis of cancer and guidance of clinical treatment (44,
45). A sensitive and unbiased isolation method to capture CTCs
is therefore essential to provide tumoral material for analysis and
potentially drive treatment decisions (46, 47).
CIRCULATING TUMOR CELL DETECTION
METHODS IN LUNG CANCER
CTCs have the potential to accompany standard screening
tests and be used for molecular characterization of a tumor
(48). Detection of CTCs in NSCLC has been challenging due
to the rarity in circulation (a few CTCs per billion normal
blood cells) and the presence of non-epithelial characteristics
(49). It is therefore imperative that sensitive and specific CTC
detectionmethods are developed and optimized to assist in better
patient monitoring and management (50–54). The advantages
and disadvantages of the isolation methods in lung cancer are
discussed and summarized in theTable 2. A summary of the CTC
lung cancer studies are highlighted in Table 3.
EX-VIVO EXPANSION OF CIRCULATING
TUMOR CELLS
Despite limitations of current CTC isolation techniques, these
cells have been detected in a number of cancers, including breast,
head, and neck cancer, lung, prostate, colon and gastric cancer
(21, 50, 53, 109, 132–135). Successful ex-vivo culture of CTCs
represents a “Holy Grail” in the study of cancer metastasis as it
allows for in depth characterization of metastasis initiating cells
as well as the testing of functional assays (136).
Short-term CTC culture (3–14 days) has been achieved in a
number of cancer types, even from early stage cancers (137–139).
This allows for the recapitulation of the disease in an ex vivo/in
vivo setting for the testing of therapies and functional analysis
(140). A summary of this is in Table 4. In comparison, long-term
cultures have only been established in advanced metastatic cases
where a large number of CTCs have been isolated (111, 142, 143)
(Table 5). Long-term culture studies have shown that some CTCs
in patient blood are immortalized and can be cultured ex vivo into
stable cell lines (Figure 1) (139). There are only a few reports of
successful long-term culture, notably, in patients with advanced
stages of disease (136, 145, 146). CTC-expansion has been limited
due to the influence of CTC enrichment. Certain cancers also
require specific culture conditions for primary and metastatic
samples (136). The successful culture of CTCs long-term holds
great promise in developing personalized cancer treatment for
testing of therapeutic efficacy using drug screening (140). This
approach could assist in determining the choice of therapeutic
regimen beneficial for patients and hence holds significance in
advancement of precision medicine and personalized oncology
(139).
Three main strategies are used for the propagation of CTCs in
culture; two-dimensional (2D) culture, very commonly used for
expansion of CTCs short-term, three-dimensional (3D) culture
used for long-term expansion and xenotransplantation and four
dimensional (4D) shown to mimic the process of metastasis
(137, 147–150).
The expansion of CTCs in-vivo to generate patient derived
xenografts (PDXs) may also be used to comprehensively analyse
advanced disease biology and present a valuable model to
understand cancer metastasis. The use of PDX’s have been shown
to mimic patient’s disease and mirror response to chemotherapy
(e.g., Platinum agents) (142, 151). However, PDXs have been
challenging due to CTC heterogeneity causing unreliability of
these models to translate clinically. PDXmodel development also
takes 4–8 months and therefore are not optimal for rapid studies
necessary for patients with advanced disease (151). In an ideal
world cancer cell lines would be routinely generated from each
cancer patient but this is not realistic at present (136, 139, 152).
CLINICAL SIGNIFICANCE
The immediate need for early detection of lung cancer recurrence
and monitoring treatment response is essential to facilitate
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TABLE 2 | The Summary of different Circulating Tumor Cell isolation methods currently used in research.
Isolation method Mode of action Advantages Disadvantages Examples
FDA approved
(clinical trials)
EpCAM positive based selection Has become the “gold standard”




CTCs can undergo EMT which
may result in reduced expression
of epithelial markers, leading to







EpCAM positive based selection Ability to process larger volumes
of blood for the capture of higher
numbers of CTCs.





Depletion of Leukocytes by
CD45 Antibodies
Has the ability to avoid
false-negative results or loss of
CTCs due to phenotypic
heterogeneity.
CTCs are often contaminated
with remaining blood cells







Cells are separated using
filtration to remove smaller cells
in the blood (e.g., White blood
cells)
Simple process. Will exclude small sized CTCs,






Isolation by Size of Epithelial
Tumor cells (ISET) (Rarecells
Diagnostics, Paris, France) (59)
Microdevice- Cote’s group (60)
Parsortix (61)




Cells are separated based on
different densities after
centrifugation.
Cells separated into distinct
layers
CTC size and density not uniform
CTCs may get lost in plasma or
by formation of CTC aggregates
Poor sensitivity





Microfluidics Cells are separated based on
their biological or physical
properties
Higher sensitivity, purity, lower
cost, reduced sample size, short
processing time, compatibility
with downstream assays
Small CTCs of comparable size
to WBCs would typically be
missed
Cell morphology may be altered
due to high shear stress during
microfiltration
Isoflux (Fluxion Biosciences) (65)




Herringbone Chip (Nagrath) (31)
Immunomagnetic Enriches target cells and
eliminates cells that are not
bound to magnetic particles
Isolate cells easily accessible Nonspecific contamination can
be from adsorption of










Electrophoresis Cells are separated based on
their electrical signature using an
electric field
Single-cell-level precision
High accuracy and precision





Cells are detected through
imaging platforms with no need
for enrichment due to
advancements in fluorescence
imaging
Multiple analysis parameters can
be used to identify and
characterize specific populations
of interest
High specificity and sensitivity.
No need for enrichment.
Potential for high speed imaging
to reduce resolution thereby
worsening accuracy.
HD-CTC (EPIC Sciences,
California) (44, 73, 74)
FastCell (SRI Biosciences) (75)
CytoTrack (Denmark) (76, 77)
improved survival of patients. Previous studies have shown
computerized tomography (CT) screening has helped to reduce
mortality, however CT has risks such as radiation exposure,
leading to an increased risk of long-term cancer (153). This
signifies the need for less invasive techniques for the early
detection ofmetastasis and aid the personalized treatment of lung
cancer. The use of CTCs as a liquid biopsy has the potential to
accompany standard screening tests and also allow for molecular
and genetic characterization of the tumor (48).
Enumeration of CTCs could provide a biomarker for cancer
surveillance following treatment of early, locally advanced and
advanced lung cancer and provided a better understanding on
the mechanisms of metastasis (33). Although chemotherapy,
targeted small molecules and immune checkpoint inhibitor
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Das et al., 2012 NSCLC 57 FastCell CTCs were detected in 42% of patients. (78)
Devriese et al., 2012 NSCLC 46 Cellsearch CTCs were detected in 62% of patients. 30% of patients positive
for CK7 and 9% positive for CK19.
(79)
Hiltermann et al., 2012 SCLC 59 Cellsearch Lower number of CTCs in patients with early stage SCLC. CTC
decrease after one cycle of chemotherapy- no change after four
cycles
(80)
Hirose et al., 2012 NSCLC 33 Cellsearch CTCs were detected in 36.4% of patients and 15.2% had five or
more CTCs before chemotherapy. No difference in response to
chemotherapy between CTC-positive and CTC-negative patients.
Progressive disease higher in CTC-positive patients.
(81)
Hofman et al., 2012 NSCLC 250 ISET CNHC’s were detected in 49% of patients corresponding to
malignant (41%), uncertain malignant (6% and benign cells (2%)
respectively.
(82)
Hou et al.. 2012 SCLC 97 Cellsearch CTCs present in 85% of patients. OS of 5.4mths for ≥50
CTCs/7.5ml blood
(83)
Illie et al., 2012 NSCLC 87 ISET CTCs positive for ALK from 5 patients corresponded to patients
having ALK-rearrangement in tumors.
(84)
Isobe et al., 2012 NSCLC 24 Cellsearch CTCs detected in 33.3% of patients (85)
Krebs et al., 2012 NSCLC 45 Cellsearch/ISET CTCs detected in 80% of patients using ISET compared to 23% of
patients using Cellsearch. Subpopulation of cells detected by ISET
did not express epithelial markers
(86)
Naito et al., 2012 SCLC 51 Cellsearch Patients with ≥8 had worse survival than those with <8 CTCs. (87)
Punnoose et al., 2012 NSCLC 41 Cellsearch CTCs were detected in 78% of patients at baseline. High baseline
CTC counts associated with response to treatment. Decreased






CTCs were successfully enriched from over 90% of patients with
breast cancer or non-small cell lung cancer.
(55)
Wendel et al., 2012 NSCLC 78 HD-CTC
assay
CTCs were detected in 73% of patients. No significant difference
between stages.
(89)
Funaki et al., 2013 NSCLC 130 Rosette Sep ITCs were detected in 74% of patients. (90)
Hosokawa et al., 2013 NSCLC 22 MCA CTCs were detected in 77% of patients using the MCA system
versus 32% using the Cellsearch system. MCA system also
isolated CTC clusters from patients identified as CTC-negative
using Cellsearch.
(91)
Ni et al., 2013 NSCLC
and
SCLC
11 Cellsearch Copy number variations reported from single CTCs similar to that
of the metastatic tumor of the same patient.
(92)
Pailler et al., 2013 NSCLC 18 Cellsearch/ISET ALK rearrangements detected in CTCs of patients with ALK







10 Cellsearch CTCs from 25% of patients were identified and single CTCs were
isolated and amplified.
(94)
Carlsson et al., 2014 NSCLC 129 HD-CTC
assay
Presence of CTM combined with clinical and imaging data
assisted in discriminating for diagnostic accuracy in all NSCLC
patients.
(95)
Earhart et al., 2014 NSCLC 6 Magnetic
Sifter
CTCs detected in 100% of patients. (96)
Illie et al., 2014 168 ISET CTCs were detected in 3% of COPD patients (97)
Juan et al., 2014 NSCLC 37 Cellsearch/ISET ALK rearrangements detected in CTCs of patients with ALK
positive NSCLC enabling monitoring and testing of crizotinib.
(98)
Marchetti et al., 2014 NSCLC 37 Cellsearch CTCs were detected in 41% of patients. EGFR mutations
identified by NGS in 84% of patients.
(99)
Muinelo –Romay et al.,
2014
NSCLC 43 Cellsearch At baseline 41.9% of patients were positive for CTCs. Patients
with ≥5 baseline had worse PFS and OS. Patients with increased
levels of CTCs has worse PFS and OS.
(100)
(Continued)
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Nel et al., 2014 NSCLC 43 Negative
depletion
Increased CD133-positive to pan-CK-positive cell type ratio (stem
like to epithelial ratio) and presence of mesenchymal
N-cad-positive cells, associated with shorter PFS.
(101)
Normanno et al., 2014 SCLC 60 Cellsearch At baseline 90% of patients were positive for CTCs and strongly
associated with organs involved. CTC reduction as high as 89%
following chemotherapy.
(102)
Chudsama et al., 2015 NSCLC 20 Screen Cell An increase in CTCs following EC observed in 75% of patients.
Could have implications for tumor dissemination and metastatic
spread.
(103)
Dorsey et al., 2015 NSCLC 23 Density
gradient
centrifugation
CTCs positive in 65% of patients. CTC count reflect clinical course
and response to treatment.
(104)
Tu et al., 2015 NSCLC
and
SCLC
18 Cellsearch CSFTC were positive in 78% of MRI confirmed LM samples.
CSFTC clusters were observed in 67% of patients.
(105)
Aieta et al., 2016 NSCLC 1 Cellsearch Presense of EML4-ALK+ CTCs at baseline. EML4-ALK+ CTCs
could be interpreted as resistance sign to crizotinib treatment
leading to progressive disease.
(106)
Cheng et al., 2016 SCLC 89 Cellsearch CTCs positive in 87.6% of patients. CTC count independent
indicator for PFS and OS.
(107)
Crosbie et al., 2016 NSCLC 27 Cellsearch CTCs positive in 22% of patients at baseline. CTC detection at
baseline associated with reduced DFS and 3-year survival.
(108)
Hanssen et al., 2016 NSCLC 48 Cellsearch CTCs positive in 15% of patients. CTC positivity was associated
with patient disease state.
(109)
He et al., 2016 NSCLC 66 Cellsearch Presence of CTCs at baseline associated with significantly shorter
PFS.
(110)
Morrow et al., 2016 NSCLC 1 Cellsearch CDX derived from CTCs enriched from NSCLC patient. (111)
Nicolazzo et al., 2016 NSCLC 24 Cellsearch Patients with PD-L1 negative CTCs all had clinical benefit, while
patients with PD-L1 (+) CTCs all experienced progressive disease.
(112)
Tan et al., 2016 NSCLC 27 ClearCell FX CTCs positive in 100% of patients, 14 were ALK-positive. (113)
Zhang et al., 2016 NSCLC 46 Negative
immunoselection
CTCs positive in 87% of patients. CTC count of more than eight
prior to chemotherapy was a strong predictor of PFS.
(114)
Chudsama et al., 2017 NSCLC 10 ScreenCell A significant increase in CTCs was observed from baseline levels
following lung manipulation.
(115)
Chudsama et al., 2017 NSCLC 23 ScreenCell CTCs positive in 78.3% and 73.9% reviewed by 2 pathologists. (116)
Coco et al., 2017 NSCLC 73 ScreenCell Baseline CTC count had no significant association with OS or PFS. (117)
Illie et al., 2017 NSCLC Cellsearch/ISET CTCs positive in 32% of patients evaluated on Cellsearch. CTCs
positive in 75% of patients evaluated on ISET. Expression of MET
was positive in 72% of cases.
(118)
Lindsay et al., 2017 NSCLC 125 Cellsearch CTCs positive in 40.8% of patients. Patients with ≥2 CTCs at




SCLC 64 Cellsearch CTCs positive in 50% of patients before treatment. Pazopanib
treatment significantly reduced proportion of patients with
increased CTC numbers. High CTC number at baseline correlated
with reduced PFS and OS. Detection of VEGFR2+ CTCs during




SCLC 108 Cellsearch CTCs positive in 60.2% of patients at baseline. Presence of
proliferative (CK67+) and non-proliferative (Ki67-), apoptotic
(M30+) and non-apoptotic (M30-) as well as EMT (Vim+) CTCs
were present in the same patient.
(121)
Pailler et al., 2017 NSCLC 39 Cellsearch/ISET Significant association between the decrease in CTC number with
ALK-CNG on crizotinib and longer PFS. ALK-CNG may be a
predictive biomarker for crizotinib efficacy in ALK-rearranged
NSCLC patients.
(122)
Salgia et al., 2017 SCLC 42 Cellsearch CTCs positive in 83% of patients at baseline. Presence of CTCs at
baseline were prognostic of shorter PFS and OS.
(123)
(Continued)
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Tong et al., 2017 NSCLC 127 Negative
immunoselection
CTCs positive in 80.31% of patients at baseline. Patients with
post-treatment increases in CTC count had poorer OS and PFS
than those without increases. Baseline CTC count and change in
CTC count during treatment were valuable prognostic indicators
for NSCLC.
(124)
Wang et al., 2017 SCLC 42 Negative
immunomagnetic
enrichment
CTCs positive in 76.19% of patients with SCLC and negative in
controls. PFS correlates with CTC numbers and the change in
CTC numbers after 1 cycle of chemotherapy.
(125)
Yang et al., 2017 NSCLC 107 Cellsearch CTCs positive in 44% of patients at baseline. CTC >5 at baseline
was a strong negative predictor of PFS and TTF. Five or more
CTCs on day 28 were strongly associated with a poor PFS.
(126)
Yuanling et al., 2017 NSCLC 105 Cellsearch CTCs positive (≥2) in 29% of patients at baseline and 9% had ≥5
CTCs. CTC count of ≥5 CTCs correlated with poor PFS and OS.
(127)
Alamgeer et al., 2018 SCLC 28 Cellsearch At baseline, two or more CTCs were detected in 86.6% of
patients.
(128)
Guibert et al., 2018 NSCLC 96 ISET CTCs positive in 93% of patients at baseline. CTCs more
frequently PD-L1+ than tissue (83 vs. 41%). Pre-treatment high
CTC counts associated with increased risk of death and
progression. Pre-treatment PD-L1+CTCs associated with bad
prognosis in patients treated with PD-1 inhibitors.
(129)
Milano et al., 2018 NSCLC 10 Density
gradient
centrifugation
CTCs undergoing EMT (CTCsEMT ) positive in 30% of patients.
CTCsEMT detection related to poor therapeutic response.
(130)
Tong et al., 2018 NSCLC 43 Negative
immunoselection
CTCs positive in 76.7% of patients at baseline. CTC count was a
strong predictor of PFS and OS.
(131)
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CTC, circulating tumor cells; CNHCs, circulating non-hematological cells; ITC, isolated tumor cells; CTM, circulating
tumor microemboli; OS, overall survival; PFS, progression-free survival; TTF, time-to-treatment failure; COPD, chronic obstructive pulmonary disease; EC, endobronchial cryotherapy;
CSFTC, cerebrospinal fluid tumor cell; MRI, Magnetic Resonance Imaging; LM, leptomeningeal metastasis; NGS, next-generation sequencing; CDX, cell line-derived xenograft.
TABLE 4 | Summary of short-term Circulating Tumor Cell culture in Lung cancer.
Study Method of CTC
isolation
CTC culture conditions Group size Morphology Reference
Zhang et al., 2014 In situ capture and
culture
4 Culture Conditions:
1. 3D co: Collagen, matrigel and cancer
associated fibroblasts (from pancreatic tumor)
2. 3D mono: Only gel culture
3. 2D co: Only cancer associated fibroblasts
4. 2D mono: No gel or fibroblasts
14 Spheroids (141)
therapies have shown significant benefits, the occurrence of
acquired drug resistance and disease relapse are very common.
Through serial sampling a longitudinal analysis of CTCs for
identification of tumor evolution could provide valuable insights
into mechanisms underlying resistance (154).
Detection of CTCs in lung cancer has been challenging,
as CTCs usually present with non-epithelial characteristics
(49). This emphasizes the need for more sensitive
technologies to better capture CTCs for in-depth
characterization and functional studies using cell culture
and xenograft models. This will then ultimately assist
in optimizing personalized therapies for lung cancer
patients, with CTCs potentially being a prognostic
biomarker.
CONCLUSION
The clinical significance of CTCs is yet to be established, however,
advances in CTC detection and single-cell profiling have
significantly improved our knowledge of underlying mechanisms
of the evolution and dissemination of cancer and is progressively
being translated to clinical studies. With lung cancer being the
largest cause of cancer mortality worldwide, one of the biggest
challenges for managing and treating patients is the lack of early
screening/diagnostic methods (4). The isolation of CTCs from
cerebrospinal fluid (CSF), may represent a unique subpopulation
CTCs with ability to survive the journey in blood circulation
and subsequent invasion of the CNS (105, 155). CTCs hold great
promise as biomarkers for the early diagnosis and treatment
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TABLE 5 | Summary of long-term Circulating Tumor Cell culture in Lung cancer.












Xenotransplantation 6 Morphology of CDX
macrometastases:
1. Clusters
2. Sheets of densely packed small








SCLC Ficoll-Hypaque RPMI 1640 medium,
serum-free (insulin,
IGF-1, selenite)





Xenotransplantation 1 Morphology of CDX
macrometastases:
1. Diffuse sheets of large polygonal
cells








Xenotransplantation 46 Cytoplasmic expressions of
chromogranin, synaptophysin and/or
CD56 as well as the lack of CD45
expression confirmed diagnosis
(144)
FIGURE 1 | Culture of circulating tumor cells.
selection of patients as well as broadening the current knowledge
of metastasis (154).
Recurrence and progress of the disease, severity of
symptoms and side-effects dramatically decrease patient’s
quality of life (QoL) (156). Therefore there is a vital
need to monitor tumor evolution and understand
mechanisms underlying development of therapeutic
resistance.
Challenges for the field to address include the low sensitivity
and specificity of current technologies prohibiting their use in
current clinical settings, the large number of CTCs required
for the development of CTC lines and patient xenografts for
downstream functional analyses and the limited number of
CTCs frequently found in patients with early stage disease
(157). CTCs have demonstrated prognostic clinical utility
is breast, lung and prostate cancers using the CellSearch
technology (158, 159). Recent studies have demonstrated
renewed interest in the FDA-approved Cellsearch platform for
CTC PD-L1 analysis (160–162). These studies demonstrate
how CTCs could be used to identify patients for anti PD-
1/PD-L1 therapy (immunotherapy). Cellsearch relies on CTC
enrichment using EpCAM (when CTCs undergo EMT, EpCAM
is downregulated). As such the field is moving toward label-
free technologies for CTC isolation. Currently, there are
a number of technologies to enrich CTCs (i.e., Rarecyte,
iChip, ISET, DEPArray, EPISPOT etc). The current label-free
technologies are being validated for a number of cancers in
larger clinical trials (163, 164). This is highlighted by the
Cancer-ID network consortium in standardizing CTC/ctDNA
and exosome isolation, analysis and reporting (165). The current
gold standard in isolating CTCs from patient blood relies on
the EpCAM status of these cells, thereby excluding a large
majority of CTCs present in the blood of metastatic patients.
Furthermore, Cellsearch does not allow for subsequent culture
as the cells are fixed (166). CTCs as a liquid biopsy have
valuable potential to improve early diagnosis, monitoring of
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disease, and direct treatment of lung cancer, however a better
understanding of CTC biology is crucial for the field to move
forward.
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